DZ
Therapeutic Areas
Suzhou Teligene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Project 1 | Non-small cell lung cancer (NSCLC) with non-resistant rare EGFR mutations | Phase IIb |
| Project 2 | NSCLC with brain metastases and EGFR mutations | Phase IIa |
| Project 3 | HER2-positive advanced solid tumors | Phase I |
| Project 4 | Recurrent/Metastatic head and neck squamous cell carcinoma | Phase I |
| Project 5 | NTRK fusion-positive advanced solid tumors | Phase I |
| Project 6 | NTRK/ROS1/ALK fusion-positive advanced tumors | Phase I |
| Project 7 | HER2-positive advanced solid tumors | IND Submitted |